Li et al., 2022 - Google Patents
SOX chemotherapy with anti-PD-1 and iNKT cell immunotherapies for stage IV gastric adenocarcinoma with liver metastases: A case reportLi et al., 2022
View HTML- Document ID
- 10012504070296802437
- Author
- Li D
- Liu M
- Wang J
- Guo J
- Xu N
- Lu J
- Publication year
- Publication venue
- Frontiers in Immunology
External Links
Snippet
Gastric cancer (GC) is the fourth most common cancer worldwide, with overall 5-year survival rate of approximate 20%. Although multimodal treatments that combine surgery with chemotherapy and immunotherapy have been shown to improve survival, pathological …
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lee et al. | The liver–immunity nexus and cancer immunotherapy | |
| Camidge et al. | Brigatinib versus crizotinib in ALK-positive non–small-cell lung cancer | |
| Jung et al. | Chimeric antigen receptor T cell therapy targeting ICAM-1 in gastric cancer | |
| Katz et al. | HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery | |
| Kim et al. | Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study | |
| Yang et al. | Progresses and perspectives of anti-PD-1/PD-L1 antibody therapy in head and neck cancers | |
| Chougnet et al. | Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort | |
| Babiker et al. | Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma | |
| Shen et al. | Cryoablation combined with transarterial infusion of pembrolizumab (CATAP) for liver metastases of melanoma: an ambispective, proof-of-concept cohort study | |
| Zhang et al. | Successful treatment of advanced intrahepatic cholangiocarcinoma with a high tumor mutational burden and PD-L1 expression by PD-1 blockade combined with tyrosine kinase inhibitors: A case report | |
| Zhu et al. | Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer | |
| Li et al. | Case report: Antiangiogenic therapy plus immune checkpoint inhibitors combined with intratumoral cryoablation for hepatocellular carcinoma | |
| Yin et al. | A patient with failed liver transplantation after the use of PD-1 blockade combined with lenvaxen | |
| Huang et al. | Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma | |
| Fang et al. | Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study | |
| Li et al. | SOX chemotherapy with anti-PD-1 and iNKT cell immunotherapies for stage IV gastric adenocarcinoma with liver metastases: A case report | |
| Lee et al. | Composition of inflammatory cells regulating the response to concurrent chemoradiation therapy for HPV (+) tonsil cancer | |
| Chen et al. | Pembrolizumab alone or combined with chemotherapy in advanced NSCLC with PD-L1≥ 50%: results of a retrospective study | |
| Song et al. | Case report: management of recurrent ovarian squamous cell carcinoma with PD-1 inhibitor | |
| Schvartsman et al. | Rapid deep responses with nivolumab plus ipilimumab in papillary renal cell carcinoma with sarcomatoid dedifferentiation | |
| Miao et al. | Progress and remaining challenges in comprehensive gastric cancer treatment | |
| Luo et al. | Two different patients with pulmonary pleomorphic carcinoma response to PD-1 inhibitor plus anlotinib | |
| Liu et al. | Neoadjuvant camrelizumab for non-small cell lung cancer: a retrospective multicenter, real-world study (CTONG2004) | |
| Fiorica et al. | Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: A case report | |
| Xue et al. | Horizons on the therapy of biliary tract cancers: A state-of-the-art review |